Abstract
There is overwhelming evidence that the brain melanocortin system is a key regulator of energy balance, and dysregulations in the brain melanocortin system can lead to obesity. The melanocortin system is one of the major downstream leptin signaling pathways in the brain. In contrast to leptin, preclinical studies indicate that diet-induced obese animals are still responsive to the anorectic effects of melanocortin receptor agonists, suggesting the melanocortin system is an interesting therapeutic opportunity. Besides regulating energy balance, melanocortins are involved in a variety of other neuroendocrine processes, including inflammation, blood pressure regulation, addictive and sexual behavior, and sensation of pain. This review evaluates the melanocortin system function from the perspective to use specific melanocortin (MC) receptors as drug targets, with a focus on the treatment of obesity and eating disorders in humans, and the implications this may have on mechanisms beyond the control of energy balance.
Keywords: pro-opiomelanocortin (POMC) gene, melanocortin (MC)receptors, MC4 receptor knockout mice, diet-induced obesity prone (DIO-P)rats, Obesity
CNS & Neurological Disorders - Drug Targets
Title: Melanocortin Receptors as Drug Targets for Disorders of Energy Balance
Volume: 5 Issue: 3
Author(s): Roger A.H Adan and Gertjan v. Dijk
Affiliation:
Keywords: pro-opiomelanocortin (POMC) gene, melanocortin (MC)receptors, MC4 receptor knockout mice, diet-induced obesity prone (DIO-P)rats, Obesity
Abstract: There is overwhelming evidence that the brain melanocortin system is a key regulator of energy balance, and dysregulations in the brain melanocortin system can lead to obesity. The melanocortin system is one of the major downstream leptin signaling pathways in the brain. In contrast to leptin, preclinical studies indicate that diet-induced obese animals are still responsive to the anorectic effects of melanocortin receptor agonists, suggesting the melanocortin system is an interesting therapeutic opportunity. Besides regulating energy balance, melanocortins are involved in a variety of other neuroendocrine processes, including inflammation, blood pressure regulation, addictive and sexual behavior, and sensation of pain. This review evaluates the melanocortin system function from the perspective to use specific melanocortin (MC) receptors as drug targets, with a focus on the treatment of obesity and eating disorders in humans, and the implications this may have on mechanisms beyond the control of energy balance.
Export Options
About this article
Cite this article as:
Adan A.H Roger and Dijk v. Gertjan, Melanocortin Receptors as Drug Targets for Disorders of Energy Balance, CNS & Neurological Disorders - Drug Targets 2006; 5 (3) . https://dx.doi.org/10.2174/187152706777452290
DOI https://dx.doi.org/10.2174/187152706777452290 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of Action of Metformin in Type 2 Diabetes and Associated Complications: An Overview
Mini-Reviews in Medicinal Chemistry Diagnosis, Treatment, and New Developments in Preeclampsia
Current Women`s Health Reviews Nanotechnology can Provide Therapeutic Agent by Targeting Molecular Structures of SARS-CoV-2 (COVID-19): A Mini-Review
Letters in Drug Design & Discovery Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews Development and Evaluation of Transdermal Organogels Containing Nicorandil
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial (Thematic Issue: “Pregnancy in Women with Metabolic Syndrome”)
Current Pharmaceutical Biotechnology Retracted: Potential Health Benefits of Broccoli- A Chemico-Biological Overview
Mini-Reviews in Medicinal Chemistry Changes in Serum Nampt Levels and Its Significances in Diabetic Nephropathy Patients-The Potential Role of Nampt in T2DM with Diabetic Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration
Current Genomics Risk Factors and Potential Preventive Measures for Vascular Disease Progression in Hemodialysis Patients
Vascular Disease Prevention (Discontinued) Spinophilin: A New Tumor Suppressor at 17q21
Current Molecular Medicine Synthesis of Natural and/or Biologically Relevant Three-membered Heterocycles and Derivatives through Asymmetric Epoxidation, Aziridination, Azirination and Thiirination
Letters in Organic Chemistry Microparticles: From Biogenesis to Biomarkers and Diagnostic Tools in Cardiovascular Disease
Current Stem Cell Research & Therapy Adiponectin: An Endothelium-Derived Vasoprotective Factor?
Current Vascular Pharmacology Prolonged Perfusion Predicts Recurrent Ischemic Stroke but not Transient Ischemic Attack in Patients with Symptomatic Intracranial Stenosis
Current Neurovascular Research The Temporal Relationship between Pain Intensity and Pain Interference and Incident Dementia
Current Alzheimer Research Pharmacological and Cellular Therapies to Prevent Restenosis after Percutaneous Transluminal Angioplasty and Stenting
Cardiovascular & Hematological Agents in Medicinal Chemistry Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Current Cancer Therapy Reviews The Role of Pemetrexed Combined with Targeted Agents for Non-Small Cell Lung Cancer
Current Drug Targets The Role of Endogenous H2S in Cardiovascular Physiology
Current Pharmaceutical Biotechnology